Collins F M, Klayman D L, Morrison N E
Am Rev Respir Dis. 1982 Jan;125(1):58-60. doi: 10.1164/arrd.1982.125.1.58.
Determinations of minimal inhibitory concentrations (MIC) were carried out using three new 2-acetylpyridine and two new 2-acetylquinoline thiosemicarbazones tested against Mycobacterium tuberculosis, M. kansasii, M. simiae, M. avium, and M. intracellulare. Two of the compounds (Compounds L and 3I) exhibited MIC less than or equal to 5 micrograms per ml for all of the test organisms, except for M. simiae, which was resistant to most antituberculous drugs. The other thiosemicarbazones (Compounds 3L, 2N, 3G, and 2H) were relatively inactive against the nontuberculous mycobacteria. Rifampin, amikacin, and clofazimine were active when tested singly or in combination with Compounds L and 3I. Addition of compound 3I to a mixture of rifampin, amikacin, and clofazimine resulted in combination MIC of less than 0.6 microgram/ml against all of the nontuberculous mycobacteria, suggesting that combinations of this type may be suitable for the treatment of infections caused by these highly drug-resistant organisms.
采用三种新型2-乙酰基吡啶和两种新型2-乙酰基喹啉硫代卡巴腙对结核分枝杆菌、堪萨斯分枝杆菌、猿分枝杆菌、鸟分枝杆菌和胞内分枝杆菌进行最低抑菌浓度(MIC)测定。其中两种化合物(化合物L和3I)对所有受试菌的MIC均小于或等于5微克/毫升,但猿分枝杆菌除外,该菌对大多数抗结核药物耐药。其他硫代卡巴腙(化合物3L、2N、3G和2H)对非结核分枝杆菌相对无活性。利福平、阿米卡星和氯法齐明单独或与化合物L和3I联合测试时均有活性。在利福平、阿米卡星和氯法齐明的混合物中加入化合物3I,对所有非结核分枝杆菌的联合MIC均小于0.6微克/毫升,这表明这种类型的联合用药可能适用于治疗由这些高度耐药菌引起的感染。